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Abstract 
 
2’-Methoxydiphenidine, also known as 1-[1-(2-methoxyphenyl)-2-phenylethyl] 
piperidine and ‘MXP’ (or 2’-MXP), has been available as a ‘research chemical’ from 
2013 as a purported alternative to the ‘dissociative anaesthetics’ methoxetamine and 
ketamine. Three deaths which involved the detection of 2’-MXP in post-mortem blood 
and urine were encountered in forensic casework. The 2’-, 3’- and 4’- methoxyphenyl 
positional isomers were synthesized to confirm the identity and concentration of 2’-
MXP. The 2’-MXP femoral blood concentrations in the cases were found to be 24.0, 
2.0 and 1.36 mg/L (the latter with an alternative cause of death). Some additional 
prescription drugs were encountered at therapeutic levels in all three cases. Analysis 
of the biofluids allowed the detection and characterization of various metabolites, 
including the suggested presence of hydroxy-2’-MXP as the main metabolite with the 
hydroxyl group located on the piperidine rather than the phenyl or benzyl moiety. 
Additional metabolites included O-desmethyl-2’-MXP and hydroxylated O-desmethyl-
2’-MXP. Diphenidine and hydroxy-diphenidine, also showing the presence of the 
hydroxyl group on the piperidine ring, were also detected. It was not possible to 
identify whether these arose from 2’-MXP biotransformation or whether they 
represented the presence of diphenidine as a separate substance. These are the first 
published fatalities involving methoxydiphenidine and presents analytical data to 
assist analytical toxicologists with future casework.   
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INTRODUCTION 
 
The use of ‘dissociative anaesthetics’ for non-medical purposes has been observed 
since the development of the prototypical 1-(1-phenylcyclohexyl)piperidine (PCP) 
and 2-(2-chlorophenyl)-2-(methylamino)cyclohexanone (ketamine). An important 
feature linked with some of the psychoactive properties of these agents includes 
uncompetitive antagonism at the N-methyl-D-aspartate (NMDA) receptor (1-3). A 
number of arylcyclohexylamines and aryl-amino-cyclohexan-2-ones are some of the 
more commonly encountered structural templates associated with dissociative 
'research chemicals' (4, 5).   
A more recent development in the field of dissociative ‘research chemicals’ involves 
the availability of substances that display the 1,2-diarylethylamine backbone. Two 
current examples are 1-(1,2-diphenylethyl)piperidine (diphenidine) and 1-[1-(2-
methoxyphenyl)-2-phenylethyl]piperidine (2’-MeO-diphenidine, methoxphenidine, 
MXP, 2’-MXP) (Figure 1). From the perspective of the United Kingdom, it appears 
that their appearance dates back to 2013 following the control of 2-(ethylamino)-2-(3-
methoxyphenyl)cyclohexanone (methoxetamine, MXE), which attracted attention in 
the ‘research chemicals’ community (4) but also in clinical and forensic situations due 
to the observation of adverse effects (6, 7). Whilst analytical data pertaining to 
diphenidine and related analogues and isomers have recently been published (8-10), 
data for methoxy derivatives (especially in biological fluids) are currently less 
abundant. A recently published case report described the qualitative detection of 2’-
MXP in plasma and urine following acute intoxication  (11). 
 
Detailed data on the pharmacodynamics of 2’-MXP are not yet available but it has 
been previously synthesized as part of a series of 1,2-diarylethylamines that were 
investigated for their potential neuroprotective properties. Racemic 2’-MXP, when 
compared against PCP and 1-[1-(thiophen-2-yl)cyclohexyl]piperidine (TCP), was 
reported to bind to crude membrane preparations obtained from whole rat brains (1 
nM [3H]-TCP as radioligand), which implicated involvement of the NMDA receptor (Ki 
= 170 nM for 2’-MXP, 96 nM for PCP, 20 nM for TCP and 39 nM for racemic 
diphenidine, respectively) (12). In 2008, German authorities seized two 1,2-
diphenylethylamines that were subsequently identified as the monoalkylated N-ethyl 
(NE-DPEA) and N-isopropyl (NIP-DPEA) analogues of lefetamine (Figure 1) (13) and 
recent investigations of their detection in rat urine have also been reported (14). The 
1,2-diarylethylamine class and their associated pharmacological properties appear to 
be diverse in nature and difficult to predict based on structural features alone (15-19). 
With regard to the dissociative effects of diphenidine and 2’-MXP, anecdotal reports 
suggest 2'-MXP may be more potent than diphenidine but further research is 
necessary. 
 
The presence of the methoxy group on the phenyl ring gives rise to three 
methoxyphenyl positional isomers (2’-MXP, 3’-MXP and 4’-MXP). It is important in 
forensic chemistry in particular to be able to distinguish between these isomers given 
that they might display different pharmacological properties (20) This paper presents 
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analytical data pertaining to these isomers and was used to identify the form found in 
three fatalities involving 2’-MXP with subsequent quantification for the first time.  
 
Case Histories 
 
Case 1 
A 34 year old male was found dead at home. There was evidence of drug 
paraphernalia including white powder in clear bags that was later identified to be 
methoxphenidine (isomer not distinguished) by the police drug laboratory. The drug 
was found to have been purchased over the Internet from a ‘research chemical’ 
company. At autopsy, he was found to have an enlarged heart and hypertensive 
heart disease with no other contributory findings. 
 
Case 2 
A 34 year old male was found dead at home. He had a medical history of epilepsy, 
attention deficit hyperactivity disorder and social anxiety. He had been prescribed 
levetiracetam, dexamphetamine and diazepam. A sachet labelled ‘methoxphenidine 
2g’ was found in his pocket. At autopsy, he was found to have a moderately enlarged 
heart and mild atheroma with no other contributory findings. 
 
Case 3 
A 38 year old male was found dead on a road having jumped or fallen from a road 
bridge suffering fatal injuries. He had a medical history of schizophrenia. No other 
information was available. 
 
EXPERIMENTAL 
 
Instrumentation 
 
HPLC-DAD was carried out on a Dionex 3000 Ultimate liquid chromatography 
system coupled to a UV diode array detector (Thermo Fisher, St Albans, UK), using 
a Phenomenex Synergi Fusion column (150 mm x 2 mm, 4 µm) protected by a 4 mm 
x 3 mm Phenomenex Synergi Fusion guard column (Phenomenex, Cheshire, UK). 
The mobile phase consisted of 25 mM triethylammonium phosphate (TEAP) buffer 
and acetonitrile and the column temperature was maintained at 30 °C. 
 
An ABSciex 3200 QTRAP mass spectrometer coupled to an Agilent 1200 HPLC-
DAD system (ABSciex, Cheshire, UK) was used for LC-MS/MS analysis. 
Chromatographic separation was based on a Phenomenex Gemini column (150 mm 
x 2 mm, 5µm) protected by a Phenomenex Synergi Gemini 4 mm x 3 mm guard 
column (Phenomenex, Cheshire, UK). A mobile phase of 1 mM ammonium formate 
with 1% formic acid and acetonitrile (column temperature 30 °C) was used. 
 
The UHPLC-high resolution QTOF-MS system was the Agilent 6540 UHD Accurate-
Mass QTOF LC/MS coupled to an Agilent 1290 Infinity UHPLC system (Agilent, 
Cheshire, UK). Chromatographic separation was based on an Agilent Zorbax Eclipse 
Plus C18 column (100 mm x 2.1 mm, 1.8µm) (Agilent, Cheshire, UK) using mobile 
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phase of 1% formic acid and acetonitrile (column temperature 40°C). The 
methodology and parameters have been published previously (21). 
 
Reagents and standards 
 
All solvents and chemicals used, e.g. acetonitrile, 1-chlorobutane, methanol, sodium 
carbonate, sulphuric acid, formic acid, triethylammonium phosphate buffer and 
ammonium formate, were of analytical grade or equivalent from Sigma Aldrich 
(Dorset, UK) and/or Rathburn Chemicals Ltd (Walkerburn, Scotland, UK). Due to the 
unavailability of certified reference materials, all three positional isomers, i.e. 2’-, 3’- 
and 4’-MXP hydrochloride were synthesized utilizing a method published by Le Gall 
et al. (22) followed by full characterization including nuclear magnetic resonance 
spectroscopy (NMR). These were used to prepare fresh reference and calibration 
standards for the formal identification and quantitation in the specimens analyzed. 
Following determination of limit of detection (LOD) and limit of quantitation (LOQ) 
using an extended calibration range (from 0.025 and 0.078 mg/L, respectively), a 
calibration range of 0.3125, 0.625, 1.25, 2.5 and 5 mg/L was produced for 2’-MXP 
using blank equine plasma. Internal quality control standards of 0.5 mg/L and 2.5 
mg/L were also produced. Intra-day and inter-day precision and accuracy was 
determined. Where appropriate, post-mortem blood case samples were diluted in 
equine plasma (e.g. 3-, 5- or 10-fold) for matrix matching and to be within the linear 
calibration range. 
 
Extraction and analysis 
Basic back extraction using sodium carbonate buffer (with internal standards) and 1-
chlorobutane solvent extraction of the calibration and case samples was performed 
as described elsewhere (21). The chromatographic conditions for qualitative HPLC-
DAD, HPLC-MS and UHPLC-QTOF-MS analysis were based on previously 
published methods involving an acetonitrile gradient (21). Quantitative HPLC-DAD 
analysis was based on 30% acetonitrile (with 25 mM TEAP buffer) under isocratic 
elution conditions at a flow rate of 2 mL/min. 2’-MXP eluted at 4.0 minutes. 
 
RESULTS AND DISCUSSION 
 
Analysis of the 2’-, 3’- and 4’-methoxydiphenidine isomers showed that the positional 
isomer could be differentiated by HPLC-DAD retention time and UV spectrum which 
was consistent with the ability to differentiate between substituted piperazines, such 
as trifluoromethylphenylpiperazine (TFMPP) and chlorophenylpiperazine (CPP) (23). 
Specifically, 2’-MXP eluted at 8.44 minutes with a 278 nm UV max, 3’-MXP eluted at 
8.06 minutes with a 276 nm UV max and 4’-MXP eluted at 8.08 minutes with UV 
maxima at 229 and 272 nm (Figure 2). Based on these analytical data as well as LC-
MS and QTOF-MS comparison with the synthesized standards, only the 2’-MXP 
isomer was detected in the case samples. Figure 3 shows that with LC-MS there are 
numerous fragment ions produced to assist with identification and selection of 
appropriate ion transitions for targeted screening analysis. For quantitative analysis 
by HPLC-DAD, validation of the method showed accuracy and precision values of 
less than 6%, a limit of detection of 0.05 mg/L and a limit of quantitation of 0.10 mg/L 
(Table 1). 
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For case 1, 2’-MXP was found to be present at 24.0 mg/L in post-mortem femoral 
blood and was also detected in urine. Prescription drugs (mirtazapine, lamotrigine 
and citalopram) were also found at therapeutic levels and no ethanol was detected. 
The cause of death was given as ‘methoxyphenidine use and hypertensive heart 
disease’. For case 2, 2’-MXP was found to be present at 2.0 mg/L in post-mortem 
femoral blood and was also detected in urine. Prescription drugs (diazepam and 
quinine) were found at therapeutic levels and no ethanol was detected. 
Levetiracetam or dexamphetamine were not detected. The cause of death was given 
as ‘probable methoxyphenidine toxicity’ due to the absence of any other pathological 
findings. For case 3, 2’-MXP was found to be present at 1.36 mg/L in post-mortem 
femoral blood and was also detected in urine. The prescription antipsychotic drug 
risperidone was present at a therapeutic level and no ethanol was detected. The 
cause of death was due to multiple injuries following the fall and the inquest 
conclusion was “suicide whilst suffering from a mental illness”. Based on only three 
cases it is not possible to determine what concentrations may constitute excessive 
use, recreational or otherwise. The variation in concentrations fundamentally 
depends on a range of factors, such as routes of administration and dosage levels 
used but also the extent to which individuals have been aware of the drug actually 
being taken (as evidenced in two of these cases). Nevertheless, users may still not 
be aware of what dose would likely result in desired or toxic effects. Therefore, the 
concentration levels reported here are presented for future case reference only.  
Apart from a number of anecdotal reports (4), detailed information about the 
pharmacodynamic features of 2’-MXP is currently not available. It is tempting to 
consider the potential involvement of th  NMDA receptor when attempting to make 
comparisons with what has been described for diphendidine, methoxetamine and 
ketamine (1, 4, 9, 19, 24). Such effects may include drowsiness, dissociative and 
catatonic states, hallucinations, confusion and cardiovascular effects including 
hypertension and tachycardia. These potential effects were important in the 
circumstances of the three cases described here and were considered in determining 
the manner of death, irrespective of the concentration measured. However, further 
research into the pharmacological properties of these particular diarylethylamines 
seems warranted in order to elucidate additional mechanisms of actions that may be 
involved.   
During the analysis of the case samples, apparent metabolites of 2’-MXP were also 
detected. Initially, this was observed by HPLC-DAD analysis through UV spectral 
comparison with the parent molecule 2’-MXP and further confirmation was obtained 
from LC-MS investigations, which pointed towards similar fragments to 2’-MXP under 
full scan mass spectrometry conditions. When high resolution QTOF-MS analysis 
was carried out, further details about the associated empirical formulae emerged as 
summarized in Table 2 and Figure 4. These metabolites were observed in all three 
cases in both the post-mortem blood and urine samples. The suggested structural 
features associated with the detected analytes were based on previous analytical 
studies on diphenidine isomers (9). In addition to the parent molecule 2’-MXP (Figure 
4A), the primary metabolite (based on observed LC peak abundance) appeared to be 
hydroxylated 2’-MXP (Figure 4B) with a relative abundance of around 25% to that of 
2’-MXP in blood and 50% to similar abundance to 2’-MXP in urine. Other 
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hydroxylated metabolites were observed (based on the predicted empirical formula) 
but were present at significantly lower concentrations based on signal intensity 
(relative abundance of around 5% to that of 2’-MXP in blood and urine). The exact 
position of the hydroxyl group present in the main hydroxylated metabolite (Figure 
4B) remains to be confirmed but tandem mass spectral data indicated that 
hydroxylation might have occurred on the piperidine ring instead of the phenyl and 
benzyl ring. Key indicators included the presence of product ions at m/z 102 
(hydroxylated and protonated piperidine) and m/z 211 which pointed towards the 
presence of an unchanged methoxylated diphenyl product ion also present in 2’-MXP 
(Figure 4A and 4G). Correspondingly, m/z 86 and m/z 197, implied the presence of 
the less prominent O-desmethyl-2’-MXP metabolite (Figure 4C). With regard the 
metabolite suggested to be consistent with hydroxy-O-desmethyl-2’-MXP, the 
product ions at m/z 102 and m/z 197 suggested hydroxylation of the piperidine ring 
(Figure 4D). In a previously published case report, the detection of various 
hydroxylation products has also been mentioned (11). Furthermore, diphenidine 
(Figure 4E) was also detected in the present study at what appeared to be at trace 
levels in both blood and urine. Whether this was formed as a result of 
desmethoxylation, and therefore indicating a potential metabolite, or detected due to 
the presence of diphenidine as a separate compound, was unclear. However, as far 
as case 1 was concerned, the presence of diphenidine in the product was not 
reported. Figure 4F displays the QTOF-MS/MS data associated with what would 
have been consistent with a hydroxylated diphenidine metabolite where 
hydroxylation, as observed with the main metabolite of 2’-MXP described above, 
might have occurred on the piperidine ring.    
 
CONCLUSION 
 
Three fatalities associated with the ‘research chemical’ 2’-methoxydiphenidine (2‘-
MXP) are presented for the first time. In two of the cases MXP was given as the 
cause of death and in one case, death was due to a fall. The combination of HPLC-
based separation with UV full scan and high-resolution mass spectrometry allowed 
for the detection of 2‘-MXP and metabolites in both post-mortem blood and urine. 
The high abundance of the main metabolite, interpreted as h droxy-2’-MXP (on the 
piperidine ring), may be of specific analytical importance when investigating clinical 
and forensic case samples.  
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FIGURE LEGENDS 
 
Figure 1. Chemical structures of diphenidine, 2’-methoxydiphenidine (2’-MXP) and 
closely related derivatives of forensic interest.    
 
Figure 2. DAD data and HPLC retention times for three synthesized positional 
isomers of methoxydiphenidine. The differentiation was feasible based on the 
combination of UV full scan and retention time information. A: UV spectrum obtained 
from 2’-MXP standard and casework. B: UV full scan trace of 3’-MXP. C: UV full scan 
trace of 4’-MXP. 
 
Figure 3. Enhanced product ion (EPI) scan of 2’-MXP (case vs. reference material) 
at collision energy (CE) spread (35 ± 15 V) using electrospray LC-MS. 
 
Figure 4. Accurate mass fragmentation of 2’-MXP and purported metabolites 
detected in case samples.  
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Figure 3. Enhanced product ion (EPI) scan of 2’-MXP (case vs. reference material) at collision energy (CE) 
spread (35 ± 15 V) using electrospray LC-MS.  
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Figure 3. Enhanced Product Ion scan of 2’-Methoxydiphenidine at collision energy (CE) spread (35 +/- 15V) using electrospray LC-MS. 
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Table 1. Validation data for quantitation of 2’-methoxydiphenidine. 
 
Intra-day 
(n=10) 
Mean concn mg/L 
(± SD) 
Precision 
(%) 
Accuracy 
(%) 
0.1 mg/L 0.989 ± 0.015 1.5 -1.1 
    
Inter-day 
(n=6) 
   
0.5 mg/L 0.52 ± 0.01 1.2 4.6 
2.5 mg/L 2.64 ± 0.02 0.9 5.5 
    
LOD 0.05 mg/L   
LOQ 0.10 mg/L 1.5 -1.1 
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Table 2. 2’-Methoxydiphenidine (2’-MXP) and proposed metabolites found in forensic 
casework samples using UHPLC-QTOF-MS.    
 
Compound Molecular 
formula 
Theoretical 
mass [M+H]+ 
m/z found 
2’-MeO-diphenidine (2’-MXP) C20H25NO
+ 296.20089 296.20088 
Hydroxy-2’-MXP C20H25NO2
+ 312.19581 312.19556 
O-Desmethyl-2’-MXP         C19H23NO
+ 282.18524 282.18514 
Hydroxy-O-desmethyl-MXP C19H23NO2
+ 298.18016 298.18007 
Diphenidine C19H23N
+ 266.19033 266.19076 
Hydroxy-diphenidine C19H24NO
+ 282.18524 282.18521 
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